[
    "f neurodegeneration is slowed, stopped, or reversed by about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 100% within a defined period of time after administration of the pharmaceutical composition, as measured by medically recognized techniques; and/or neurodegeneration is associated with abnormal alpha-synuclein (\u03b1 S) pathology and/or dopaminergic dysfunction.</p>In another embodiment, the neurodegeneration is associated with: (a) neuronal cell death resulting from septic shock, intracranial hemorrhage, subarachnoid hemorrhage, multi-infarct dementia, inflammatory disease, nerve trauma, peripheral neuropathy, polyneuropathy, metabolic encephalopathy, and central nervous system infection; or (b) a neurodegenerative disease selected from the group consisting of synucleinopathy, alzheimer's disease, parkinson's disease, lewy body dementia, multiple system atrophy, huntington's disease, multiple sclerosis, parkinson's disease, Amyotrophic Lateral Sclerosis (ALS), schizophrenia, friedrich's ataxia, vascular dementia, spinal muscular atrophy, frontotemporal dementia, supranuclear palsy, progressive nuclear palsy, aging-related degenerative processes, senile dementia, guadeloupia parkinsonism, spinocerebellar ataxia, hallucinations, stroke, traumatic brain injury, down's syndrome, gaucher's disease, Krabbe's Disease (KD), lysosomal disorders affecting sphingoglycolipid metabolism, cerebral palsy and epilepsy; or (c) a psychological or behavioral disorder; or (d) a psychological or behavioral disorder selected from the group consisting of abnormal locomotor and obsessive-compulsive behavior, sleep disorders, REM sleep behavior disorders (RBD), depression, major depression, agitation, anxiety, confusion, irritability, ADHD, apathy, bipolar disorders, disinhibition, addiction, hallucinations and delusions, amnesia, and autism; or (e) a cerebral ischemic disorder or a general ischemic disorder; or (f) a cerebral ischemic disorder selected from the group consisting of cerebral microvascular disease, cerebral ischemia in the apical area of the brain, cerebral ischemia during/after cardiac arrest or resuscitation, cerebral ischemia due to problems in surgery, cerebral ischemia during carotid artery surgery, chronic cerebral ischemia due to stenosis of the arteries supplying blood to the brain, venous sinus thrombosis or thrombosis of the cerebral veins, cerebrovascular malformations and diabetic retinopathy; or (g) a general ischemic disorder selected from the group consisting of hypertension, hypercholesterolemia, myocardial infarction, cardiac insufficiency, heart failure, congestive heart failure, myocarditis, pericarditis, pericardial myocarditis, coronary heart disease, angina pectoris, congenital heart disease, shock, limb ischemia, renal artery stenosis, diabetic retinopathy, thrombosis a",
    "ersed by about 5%, about 10%, about 15%, about 20% within a defined period of time as measured by medically recognized techniques, About 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 100%.</p>In another aspect of the invention, neurodegeneration is associated with abnormal alpha-synuclein (\u03b1 S) pathology and/or dopaminergic dysfunction.</p>The invention also includes methods of treating and/or preventing neurodegeneration, wherein the neurodegeneration is associated with: (a) neuronal cell death resulting from septic shock, intracranial hemorrhage, subarachnoid hemorrhage, multi-infarct dementia, inflammatory disease, nerve trauma, peripheral neuropathy, polyneuropathy, metabolic encephalopathy, and central nervous system infection; or (b) a neurodegenerative disease selected from the group consisting of synucleinopathy, alzheimer's disease, parkinson's disease, lewy body dementia, multiple system atrophy, huntington's disease, multiple sclerosis, parkinson's disease, Amyotrophic Lateral Sclerosis (ALS), schizophrenia, friedrich's ataxia, vascular dementia, spinal muscular atrophy, frontotemporal dementia, supranuclear palsy, progressive nuclear palsy, aging-related degenerative processes, senile dementia, guadeloupia parkinsonism, spinocerebellar ataxia, hallucinations, stroke, traumatic brain injury, down's syndrome, gaucher's disease, Krabbe's Disease (KD), lysosomal disorders affecting sphingoglycolipid metabolism, cerebral palsy and epilepsy; or (c) a psychological or behavioral disorder; or (d) a psychological or behavioral disorder selected from the group consisting of abnormal locomotor and obsessive-compulsive behavior, sleep disorders, REM sleep behavior disorders (RBD), depression, major depression, agitation, anxiety, confusion, irritability, ADHD, apathy, bipolar disorders, disinhibition, addiction, hallucinations and delusions, amnesia, and autism; or (e) a cerebral ischemic disorder or a general ischemic disorder; or (f) a cerebral ischemic disorder selected from the group consisting of cerebral microvascular disease, cerebral ischemia in the apical area of the brain, cerebral ischemia during/after cardiac arrest or resuscitation, cerebral ischemia due to problems in surgery, cerebral ischemia during carotid artery surgery, chronic cerebral ischemia due to stenosis of the arteries supplying blood to the brain, venous sinus thrombosis or thrombosis of the cerebral veins, cerebrovascular malformations and diabetic retinopathy; or (g) a general ischemic disorder selected from the group consisting of hypertension, hypercholesterolemia, myocardial infarction, cardiac insufficiency, heart failure, congestive heart failure, myocarditis, pericarditis, pericardial myocarditis, coronary heart disease, angina pectoris, congenital heart disease, shock, limb ischemia, renal artery stenosis, diabetic retinopathy, thrombosis a",
    "east about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100%, as measured using clinically accepted scales or tools.</p>In one aspect, the neurodegeneration associated with aberrant \u03b1 S pathology and/or dopaminergic dysfunction is involved in or associated with a neurodegenerative disease or neurological disease associated with neuronal cell death. In another aspect, the neurodegenerative disease or neurological disease or associated symptom associated with neuronal cell death: (a) selected from the group consisting of septic shock, intracranial hemorrhage, subarachnoid hemorrhage, multi-infarct dementia, inflammatory disease, nerve trauma, peripheral neuropathy, polyneuropathy, metabolic encephalopathy, and central nervous system infection; or (b) is selected from the group consisting of synucleinopathies, alzheimer's disease, parkinson's disease, lewy body dementia, multiple system atrophy, huntington's disease, multiple sclerosis, parkinson's disease, Amyotrophic Lateral Sclerosis (ALS), schizophrenia, friedrich's ataxia, vascular dementia, spinal muscular atrophy, frontotemporal dementia, supranuclear palsy, progressive nuclear palsy, age-related degenerative processes, senile dementia, guadeloupia parkinsonism, spinocerebellar ataxia, hallucinations, stroke, traumatic brain injury, down's syndrome, gaucher's disease, Krabbe's Disease (KD), lysosomal disorders affecting the metabolism of glycosphingolipids, cerebral palsy and epilepsy.</p>In another aspect, the neurodegeneration associated with aberrant \u03b1 S pathology and/or dopaminergic dysfunction is related to or associated with a psychological or behavioral disorder. For example, the psychological or behavioral disorder may be selected from the group consisting of abnormal motor and obsessive compulsive behavior, sleep disorders, REM sleep behavior disorders (RBD), depression, major depression, agitation, anxiety, confusion, irritability, ADHD, apathy, bipolar disorders, disinhibition, addiction, hallucinations and delusions, amnesia, autism.</p>In one embodiment, the neurodegeneration associated with aberrant \u03b1 S pathology and/or dopaminergic dysfunction is related to or associated with a cerebral ischemic disorder or a general ischemic disorder. For example, the cerebral ischemic disorder may be selected from cerebral microvascular disease, cerebral ischemia in the apical area of the brain, cerebral ischemia during/after cardiac arrest or resuscitation, cerebral ischemia due to problems in surgery, cerebral ischemia during carotid artery surgery, chronic cerebral ischemia due to stenosis of the arteries supplying blood to the brain, venous sinus thrombosis or thrombosis of the cerebral veins, cerebrovascular malformations, and diabetic retinopathy; or the general ischemic disorder may be selected from hypertension, high cholesterol, myocardial infarcti"
]